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Abstract
Background
Metastatic melanoma is still one of the most prevalent skin cancers, which upon progression
has neither a prognostic marker nor a specific and lasting treatment. Proteomic analysis is a
versatile approach with high throughput data and results that can be used for characterizing
tissue samples. However, such analysis is hampered by the complexity of the disease, het-
erogeneity of patients, tumors, and samples themselves. With the long term aim of quest for
better diagnostics biomarkers, as well as predictive and prognostic markers, we focused on
relating high resolution proteomics data to careful histopathological evaluation of the tumor
samples and patient survival information.
Patients and methods
Regional lymph node metastases obtained from ten patients with metastatic melanoma
(stage III) were analyzed by histopathology and proteomics using mass spectrometry. Out
of the ten patients, six had clinical follow-up data. The protein deep mining mass spectrome-
try data was related to the histopathology tumor tissue sections adjacent to the area used
for deep-mining. Clinical follow-up data provided information on disease progression which
could be linked to protein expression aiming to identify tissue-based specific protein markers
for metastatic melanoma and prognostic factors for prediction of progression of stage III
disease.
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Results
In this feasibility study, several proteins were identified that positively correlated to tumor tissue
content including IF6, ARF4, MUC18, UBC12, CSPG4, PCNA, PMEL and MAGD2. The study
also identified MYC, HNF4A and TGFB1 as top upstream regulators correlating to tumor tissue
content. Other proteins were inversely correlated to tumor tissue content, the most significant
being; TENX, EHD2, ZA2G, AOC3, FETUA and THRB. A number of proteins were significantly
related to clinical outcome, among these, HEXB, PKM and GPNMB stood out, as hallmarks of
processes involved in progression from stage III to stage IV disease and poor survival.
Conclusion
In this feasibility study, promising results show the feasibility of relating proteomics to histo-
pathology and clinical outcome, and insight thus can be gained into the molecular processes
driving the disease. The combined analysis of histological features including the sample cel-
lular composition with protein expression of each metastasis enabled the identification of
novel, differentially expressed proteins. Further studies are necessary to determine whether
these putative biomarkers can be utilized in diagnostics and prognostic prediction of meta-
static melanoma.
Introduction
Cutaneous metastatic melanoma (MM) is the sixth most common cancer worldwide with an
increasing incidence especially in the Northern European countries and Australia [1, 2]. In
Sweden it is the fifth most prevalent malignant neoplasm both in men (following prostate,
colon, non-melanocytic skin and urinary tract tumors) and women (following breast, colon,
non-melanocytic skin and uterine neoplasms) with an annual incidence of 5% [3, 4].
Malignant melanoma possessing a wide variety of cytomorphologic features can be consid-
ered as a challenge from a diagnostic perspective, and is well-known for its metastatic spread,
most common to the lungs, liver, brain, bone and skin but sometimes to any, and often
unusual location in the body. Melanoma tumors commonly possess a broad toolkit to escape
from the body surveillance system [5] thus facilitating further metastatic spread. Examples of
such mechanisms are replicative immortality, genome instability and mutation, resistance to
cell death, deregulated cellular energetics, sustaining proliferative signaling, evasion of growth
suppressors, activation of invasion and metastasis, tumor promoting inflammation and means
to avoid immune destruction [6].
Screening and early detection improve survival from MM and a better outcome can be
expected once surgical removal of early primary lesion was performed, still about 15–25% of
the sentinel lymph nodes contain metastatic melanoma cells [7]. Progression from the lymph
nodes may occur with time, and metastatic melanoma has been inherently difficult to treat
with a low survival rate (< 15% at 5 years) [8]. A phase 3 clinical trial (Multicenter Selective
Lymphadenectomy Trial II, or MSLT-II) is designed and conducted to answer the question
whether sentinel lymph node biopsy should routinely be followed by removal of the remaining
regional lymph nodes (complete lymph node dissection) if the sentinel lymph node is positive
for melanoma, or it should be followed-up by ultrasound [9]
Factors determining prognosis routinely rely on clinicopathological characteristics of the
patient and primary tumor [10–13], which have been supplemented with DNA sequencing
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studies in the past years [14–20]. Most melanomas harbor alterations in the BRAF, NF1, RAS,
MDM2 (KIT) genes, which result in activation of the MAPK and RAS pathways conferring
survival advantage by reprogramming crucial cell cycle and apoptotic cellular functions [21].
Clinical and pathological properties partly reflect the identified (BRAF, RAS, NF1, triple wild
type) genomic subtypes of melanoma, but from both clinical and genetic perspective the
groups still are heterogeneous [21].
Newly developed drugs allowing targeted therapy such as kinase inhibitors or drugs modu-
lating the immune response currently provide more promise to the patients [22–27]. However,
some of these newer treatments have also been subjected to the development of resistance [28].
Recently, the Food and Drug Administration (FDA) approved nivolumab (Opdivo), a PD-1
immune checkpoint inhibitor, for the treatment of advanced (unresectable or metastatic) mel-
anoma in adults, regardless of BRAF status. The drug was approved by FDA for the treatment
of patients both with BRAF V600 wild-type unresectable and BRAF V600 mutation-positive
metastatic melanoma in addition to combination treatment with ipilimumab (anti-CTLA-4
antibody). With several options requiring individualized treatment, there is a great demand
for validated biomarkers that can support both the primary diagnosis and preferably predict
the progression of disease and response to treatment of metastatic disease. Predictive biomark-
ers of response to immune checkpoint inhibitors are currently under evaluation including but
not limited to the lymphocytic infiltration of the tumor (= the immunoscore) [29], PD-L1
expression and or CTLA-4 expression [30].
Building upon our previous proteomics work [31] and related genomics studies [32–34],
proteomics data for samples from 10 patients with lymph node metastatic melanoma (PRIDE
dataset identifier: PXD001725) were referred to histopathological and clinical work-up and
evaluation.
Thus, in this feasibility study, in addition to the deep mining proteomic analysis utilizing
high-resolution reversed phase nano-separation in combination with mass spectrometry, we
also performed in depth pathological characterization (including tissue composition, tumor
characteristics and lymphocytic infiltration). The pathological analyses were performed on
tumor tissues sections adjacent to the areas used for deep mining. Clinical follow-up informa-
tion of the patients was reviewed and the cases were grouped into prognostic sets. Hence, the
protein expression could be related to the specific cellular composition of the sample. Based on
identified protein signatures, molecular classification and clinicopathological characterization,
emerging biological relevance could be assigned to several marker proteins.
Materials and methods
Clinical samples
The location of primary tumors and progression of melanomas is displayed in Fig 1. This
study was approved by the Regional Ethical Committee at Lund University, Southern Sweden,
approval number: DNR 191/2007 and 101/2013. All patients within the study provided a
written informed consent. The tumor tissues used were lymph node metastases from 10 mela-
noma patients undergoing surgery at Lund University Hospital, Sweden. The clinical informa-
tion on respective patients is summarized in Table 1. The fresh specimens were divided into
two parts. One portion of the metastasis was fixed in formalin, embedded in paraffin (FFPE)
and subsequently sectioned for histopathologic confirmation and the other part was snap fro-
zen within minutes after removal and stored at -80˚C in the Biobank. All FFPE samples were
routinely confirmed for diagnosis at the department of surgical pathology. The frozen speci-
mens were used as described below for both protein expression analysis and further histologi-
cal evaluations.
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Histological evaluation of tumors
Frozen tissue samples were sectioned on a cryostat into 6 μm thick sections, placed upon glass
slides, dried at 37˚C for 30 min and fixed with 100% methanol for 5 min. The sections were
stained with hematoxylin and eosin (HE) [35]. Histological examination was performed on
sections immediately neighboring on both sides those sections that were solubilized and sub-
jected to LC-MS/MS investigation. The tumor samples were analyzed for their contents
regarding ratio of neoplastic area, adjacent lymph node area, necrosis and connective tissue
including fat, fibrous tissue or other material. The tumor parameters were grouped and scored
as referenced [21]: tumor cell size was initially measured and assigned as< 20 um, 20–25 um,
> 25 um; tumor cell shape was classified as epithelioid, spindle or mixed; pigmentation was
scored as 0–3 (0 = no melanin pigment, 1 = slight melanin pigmentation visible at high power,
2 = moderate pigmentation visible at low power, 3 = high pigmentation readily visible at low
Fig 1. Location of primary tumors on the body of melanoma patients and their route of progression. Red font represents poor prognosis (“non-
survivors”), green font represents good prognosis (“survivors”).
https://doi.org/10.1371/journal.pone.0176167.g001
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power with dense melanin content); predominant cytoplasmic properties were assigned as
unremarkable, eosinophilic or mixed. The lymphocytic infiltration in two dimensions (distri-
bution: 0: no infiltration, 1: less than 25% of tumor infiltrated, 2: 25–50% of tumor infiltrated,
3: more than 50% of tumor infiltrated by lymphocytes; density was assessed on a 0–3 semi-
quantitative scale) was assessed resulting in a combined (lymphocyte distribution + lympho-
cyte density) = immunoscore (sum of components: 0, 2–6).
Prognostic grouping of patients based on clinical follow-up data
For prediction of occurrence of distant organ metastases and eventually, survival we have
reviewed the clinical history and the follow-up information on all 10 patients. Overall survival
(OS) and disease-specific survival (DSS) of the patients were available. Kaplan-Meier survival
curve supported by log-rank test was constructed (Fig 2A). In order to relate protein expres-
sion data to clinical outcome, we have identified a group of “survivors” (group 1 in Fig 2A, 2B
and 2C), who did not develop any further recurrence of the neoplastic disease on a long-term
follow-up period (range = 4353–7960 days) as compared to”non-survivors” (group 2 in Fig
2A, 2B and 2C) who have progressed to stage IV cancer and eventually succumbed to wide-
spread malignant melanoma (range = 451–591 days). We excluded those cases, which had
tumor tissue of less than 10% on the slides (Fig 2C), and one case which deceased without evi-
dence of malignancy (Fig 2C). The characteristics of the tumors of the clinically and patholog-
ically stratified patients are displayed in Table 2.
Proteomics data
Proteomics data were used, as deposited in the PRIDE database, under the dataset identifier
PXD001725 [31]. At least two unique peptides were necessary for protein identification, and at
the parameter Peptide Confidence in Proteome Discoverer was required to be “high”.
Bioinformatics
Initial functional analysis of protein lists used the DAVID and ConsensusPathDb tool sets [36,
37]. Enrichment of the lists in particular functional annotations was assessed by Fisher’s exact
test with Benjamini correction for multiple tests. Gene Ontology annotations, SwissProt
Table 1. Clinical information of patient characteristics. Breslow thickness and Clarks refer to primary melanoma feature.
Tumor Gender Age at met Age at primary Breslow class Clark Stage Status OS DSS
MM35 Male 55 54 3 4 3 Alive 7960 -
MM98 Male 75 73 4 4 3 Dead 519 519
MM504 Male 54 NA NA NA NA Dead 451 451
MM687 Male 74 72 1 2 3 Dead 591 591
MM787 Male 81 78 2 4 3 Dead 734 734
MM812 Male 51 NA NA NA NA Alive 5028 -
MM813 Female 54 54 2 3 3 Alive 4913 -
MM825 Female 66 64 2 4 3 Alive 4508 -
MM829 Male 55 49 1 2 3 Alive 4431 -
MM835 Female 36 32 3 3 3 Alive 4353 -
NA–not available
OS–Calculated from date of sample collection to 20160622.
DSS–Calculated from date of sample collection to date of dead in melanoma disease.
https://doi.org/10.1371/journal.pone.0176167.t001
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keywords, and KEGG pathways were used as annotation terms for the enrichment analysis.
For lists of proteins with significantly changed expression, the background protein sets con-
sisted of all proteins detected. Other visualizations, list manipulations and charts were con-
ducted in Spotfire (Tibco Software, Inc., Palo Alto, CA, USA).
Investigation of correlations between protein expression data and histopathology was per-
formed for histological parameters: 1) tumor percentage, 2) connective tissue percentage, 3)
adjacent lymph node area and 4) immunoscore. Herein, for protein expression, detection
count was used as proxy for abundance. With triplicate proteomics analysis of every patient
sample, detection count ranged from zero to three. Spearman rank correlation was used, in
home-made scripts within the R environment.
For statistical analysis of significant differences in protein occurrences between the clinical
“survivors” and “non-survivors” patient sample sets, t-test was applied as implemented in the
Perseus toolkit (http://www.coxdocs.org/doku.php?id=perseus:start). For the purpose of this
test, for each protein total PSM count was used as proxy for protein abundance, thus the t-test
compared 9 vs. 9 samples for every protein (3 patients per group times 3 replicates).
For in-depth functional analysis of the set of differentially regulated proteins (“survivors”
vs. “non-survivors”) and of the set of proteins correlated significantly with sample tumor con-
tent, QIAGEN’s Ingenuity Pathway Analysis (Qiagen, Redwood City, CA, USA) was used to
generate relationship networks, and perform additional functional analyses.
Results and discussion
Histological characterization
The pathological evaluation is based on general directives of pathological assessment of tumor
landmarks which is comparable to other studies previously performed [21], in addition to the
Fig 2. (A) Overall survival of the prognostic groups, “survivors” (group 1) and “non-survivors” (group 2). (B) All ten cases were subjected to rigorous review
both on histological and clinical grounds. (C) Those were omitted (lighter grey text), where the tumor content of the examined tissue was low (<10%) or the
clinical follow-up data resulted in non-disease-specific outcome measures (one patient in group 2 died without evidence of malignancy). Abbreviations: l:
left; r: right; LN met: lymph node metastasis; CNS: central nervous system; tx: therapy. Numbers in brackets mean lymph nodes containing metastatic
melanomas / all lymph nodes dissected from either the groin or the axilla: nmetastatic/nall.
https://doi.org/10.1371/journal.pone.0176167.g002
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detailed pathophysiological disease status that each patient´s tissue represents. The first section
of tumor tissue was stained with HE, the adjacent sections were subjected to proteomic analysis,
and finally the last section was stained with HE and was also characterized by histology. The gen-
eral tumor cell content of lymph nodes containing metastasis tissues was assessed, and percent-
ages of identified areas were recorded. The melanoma metastases were also characterized for
their cytological appearance: tumor cell size and shape, predominant cytoplasmic appearance in
line with pigmentation. A pigment score and lymphocyte distribution and density were assessed
resulting in a combined immunoscore as described in Materials and Methods (Table 2).
Our previous genomics study using the same patient samples [32], identified “high
immune” and the “pigmentation” subtypes of melanoma metastases. Here, we assessed the
tumors independently of their intrinsic genomic subtype. All melanoma metastases were
Table 2. Histopathological properties of the melanoma metastases evaluated in this study. The ten tumors are grouped according to clinicopathologi-
cal classification.
GROUPING Clinicopathologic
All Equivocal* "survivors" "non-survivors"
Tumor cell size <20 microns 10 4 3 3
20–25 microns 0 0 0 0
>25 microns 0 0 0 0
Tumor cell shape epithelioid 7 2 2 2
Spindle 0 0 0 0
Mixed 3 1 1 1
Pigment score 0 2 1 1 0
1 2 0 0 1
2 2 1 1 0
3 4 1 1 2
Cytoplasm eosinophilic 10 4 3 3
Unremarkable 0 0 0 0
Mixed 0 0 0 0
Lymphocyte distribution 0 0 0 0 0
1 4 1 1 2
2 3 2 1 1
3 1 0 1 0
Lymphocyte density 0 0 0 0 0
1 6 2 1 2
2 2 1 1 1
3 0 0 0 0
Immunoscore (= lymphocyte density+ lymphocyte distribution) 0 0 0 0 0
2 3 1 1 1
3 4 0 1 1
4 0 1 0 0
5 1 0 1 0
6 0 0 0 0
Tumor (%) Avg 59.4 21.3 74.6 94.6
Adjacent lymph node area (%) Avg 27.0 50.5 21.8 0.5
Necrosis (%) Avg 0 0 0 0
Connective tissue content (%) avg 13.7 27.8 3.5 4.8
* equivocal cases represent those cases, which had tumor tissue of less than 10% on the slides, and one patient who deceased without evidence of
malignancy.
https://doi.org/10.1371/journal.pone.0176167.t002
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composed of generally small sized tumor cells (< 20 microns) with a predominantly eosino-
philic cytoplasm (100%, for both properties). The shape of tumor cells was mostly epithelioid
in 7 (70%) cases, while presence of admixed spindle morphology was noted in 3 (30%) cases.
Melanin pigment was noted as follows; two score 0, two score 1, two score 2 and four score 3
cases were observed. Immunoscore could only be established in 8 cases, because the amount of
tumor was too low (10%) in two cases for accurate assessment. The lymphocyte distribution
was lower than 25% of the tumor in 4 cases, was more widespread (25–50%) in 3 cases and
extensive (>50%) in 1 case. The density of lymphocytes was mostly low (score 1) in 6 cases
and moderate (score 2) in 2 cases. The combined immunoscore was 2, 3 and 5 in three, four
and one case, respectively (Table 2).
Correlation of protein expression to histological evaluation
In this study, applying conservative criteria, more than 3000 proteins were detected in meta-
static melanoma samples [31]. Investigation of correlations between protein expression data
and histopathology was performed for histological parameters: 1) tumor percentage, 2) “back-
ground” connective tissue percentage, 3) adjacent lymph node area and 4) tumor immuno-
score. Herein, for protein expression, detection count was used as proxy for abundance. With
triplicate proteomics analysis of every patient sample, the detection count ranged from zero to
three. A downside to this approach was the fact that correlation could not be calculated for 159
proteins detected in each sample.
The correlation of protein expression to tumor percentage and to immunoscore were them-
selves significantly correlated (r = 0.57, p-value < 10−5). Among the 288 proteins significantly
positively correlated to tumor percentage (shown in S1 Table), there were four proteins clearly
labelled as melanoma markers: melanoma cell adhesion molecule (MUC18) [38], melanoma
chondroitin sulfate proteoglycan (CSPG4) [39], melanocyte protein (PMEL, melan A), mela-
noma-associated antigen D2 (MAGD2). Among melanoma markers and proteins linked to
this disease, alpha-synuclein and PMEL were significantly correlated to tumor percentage
while S100A1 had correlation close to significance at r = 0.61 (p = 0.06. However, S100B had a
low correlation to tumor percentage at r = 0.32 (p = 0.37). As many as 71 proteins were nega-
tively correlated to tumor content, however, these may be specific to non-tumor cell types
(connective tissues and/or adjacent lymph node) rather than being specific to lack of tumor
shown in S2 Table.
An analysis of functional annotations over-represented among proteins correlated to
tumor percentage was performed using the ConsensusPathDB and DAVID systems. Both
analyses brought similar conclusions. Aminoacyl-tRNA- biosynthesis tRNA-charging was one
of top pathways and biological processes significantly related to the protein set. This outcome
was due to the fact that nine aminoacyl-tRNA-synthetases were significantly correlated to
tumor percentage. These were those for Gln, Thr, Val, Cys, Asp, Ala, His, Arg and Ile, with the
r correlation coefficient ranging from 0.67 to 0.81. Aminoacyl tRNA synthetases are believed
to be involved in tumorigenesis presumably involving their additional domains which are not
directly responsible to their biosynthetic activities [40]. Recently, one aminoacyl tRNA synthe-
tase was used as a cancer drug target [41]. Other pathways and processes manifested by the
proteins correlated to tumor percentage, include mitochondrial proteins (more than 80
among significantly correlated) and N-cadherin signaling (including catenins alpha-1, beta-1
and delta-1).
The set of proteins significantly correlated to tumor percentage was also subjected to
Ingenuity Pathway Analysis (IPA) system. Among the “Canonical Pathways” significantly
enriched in the protein set, tRNA-charging (p = 2,7E-08, 11 proteins out of 82) and Protein
Deep sequencing and clinicopathological analysis of lymph node metastatic melanoma
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Ubiquitination Pathway (p = 4,7E-08, the set included 18 proteins out of 259 pathway pro-
teins) were most significantly related to the protein set. Other canonical pathways included
Clathrin-mediated Endocytosis Signaling, Remodeling of Epithelial Adherens Junctions,
Acute Phase Response Signaling, Fatty Acid β-oxidation I, EIF2 Signaling. Most of these path-
ways were implicated in melanoma [42–44]. Ingenuity Pathway Analysis system also yields
deduced upstream regulators of a gene set. In the case of proteins correlated to tumor content,
the top upstream regulators were MYC, HNF4A and TGFB1, each regulating more than 50
proteins from the query set. For MYC and TGFB1, their roles in melanoma are well-estab-
lished [45, 46]. Among the general functional annotations over-represented in the query pro-
tein set, Cell Death and Survival, Cellular Growth and Proliferation, and Cellular Movement
were most significant.
Another application of IPA was “Core Analysis” that considers the overall network of rela-
tionships between all human proteins and extracts sub-networks enriched in query proteins.
Here, for the set of proteins correlated to tumor content, three top sub-networks, were
enriched in molecules involved in Molecular Transport, Protein Trafficking, Cell Signaling (1st
subnetwork, S1A Fig), DNA Replication, Recombination, and Repair, Cellular Assembly and
Organization, Cell-To-Cell Signaling and Interaction (2nd subnetwork, S1B Fig) and Cancer,
Organismal Injury and Abnormalities (3rd subnetwork, S1C Fig).
Correlation of protein expression to disease outcome
In order to relate, in a currently performed pilot analysis, protein expression in metastatic
lymph nodes to patient survival, a t-test was performed, by comparing for every protein, the
sum of PSM counts (as proxy for protein abundance) between three survivors and three non-
survivors. The results (see Fig 3A and S3 Table) showed a number of significant differences,
suggesting that even for these very low patient numbers, some trends can be observed. As
many as 36 proteins had the t-test p-value below 0.001, and 74 proteins had p-value below 0.01
(Fig 3B). Majority of significant proteins had higher expression in non-survivors. The only
well-established melanoma marker in that group was PMEL (almost 8-fold more abundant in
patients who progressed). However, many proteins from this list have previously been linked
to melanoma in the literature (Fig 3C).
Strikingly, most significant in relation to patient survival is HEXB, or Beta-hexosaminidase
subunit beta. This lysosomal enzyme is involved in hydrolysis of gangliosides GM2 to GM3. A
recent study by Tringali et al showed that poor survival in melanoma is significantly related to
GM3 levels [47]. These data agree well with our preliminary finding of elevated HEXB levels in
patients with poor survival. Another study reported that increased levels of a related ganglio-
side GD3 increase malignant properties of melanoma cells [48], thus supporting the hypothesis
that imbalance in ganglioside forms may contribute to melanoma severity and poor survival.
The HEXB protein was also noted by Byrum et al as differing between primary melanoma,
benign nevi and MM, but the direction of changes they reported was different [49].
Other proteins most significantly differing between survivors and non-survivors were
GPNMB (glycoprotein non-metastatic melanoma protein B, a homologue of PMEL) and PKM
(pyruvate kinase, muscle) hemopexin (HPX), complement factors (C3, C4B and CFH) and
vinculin (VCL), Annexin A5 (ANXA5), V-type proton ATPase catalytic subunits (ATP6V1A,
ATP6V1B2) and two aminoacyl tRNA ligases (VARS and IARS2). GPNMB was shown previ-
ously to be linked to metastasis, and is in clinical trials for melanoma [50]. PKM controls gly-
colysis, a process crucial for metabolism in malignant cells, and the balance of splicing-derived
PKM isoforms is known to be related to cancer invasiveness [51, 52]. The Complement C3a
Receptor signaling has been very recently shown to contribute to melanoma tumorigenesis
Deep sequencing and clinicopathological analysis of lymph node metastatic melanoma
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Fig 3. (A) Volcano plot showing differences in approximate protein abundance between survivors and non-
survivors. T-test p-value and mean fold difference shown (protein abundance evaluated as sum of PSMs). (B)
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[53]. On the contrary, differential expression of vinculin between weakly and highly metastatic
melanoma cell lines was noted more than 20 years ago [54].
The IPA analysis was performed for the sets of proteins that differed between survivors and
non-survivors (S2 Fig and S3A–S3D Fig). Core IPA analysis revealed that most significant
canonical pathway enriched in the set of proteins changed between survivors and non-survi-
vors was glycolysis (p-value 9.8E-13) while cell death and survival, carbohydrate metabolism,
cellular movement, and cellular growth and proliferation were the most significant biological
functions overrepresented in this protein set. This is consistent with biological processes
known to be related to metastatic properties of cancer.
Despite a very small number of patients in this pilot evaluation, (three survivors and three
non-survivors), a number of proteins were found to differentiate the two groups, and substan-
tial number of these was previously linked to cancer in the literature (S2 Fig). Among the pro-
teins most significantly differentiating between the two patient groups, HEXB, PKM and
GPNMB stood out, as hallmarks of processes involved in melanoma progression and responsi-
ble for poor survival.
Conclusion
An in depth pathological analysis of metastatic melanoma samples used for generating deep
mining high-quality mass spectrometry data of protein expression is presented. This feasibility
study provides an example how clinical outcome and detailed histopathology analysis related
to proteomics discovery data can provide novel insights into the molecular processes driving
the disease. The main implication of this study is that melanoma proteomics should be insepa-
rable from histological evaluation performed in the most detailed manner. This unique
approach is the main strength of this study while it has obvious limitations arising from
As in (A), but only significant proteins shown (p<0.05). (C) Biological relationship network (IPA) for proteins
differentiating between survivors and non-survivors (shown in B), and having literature links to melanoma or
metastasis. Only significant proteins shown (T-test p-value below 0.01), excluding proteins having no IPA
relationships within the presented set.
https://doi.org/10.1371/journal.pone.0176167.g003
Fig 4. Identified melanoma markers and pathobiological processes in tissue samples of melanoma
lymph node metastases. The graphics displays key upstream regulators found according to analysis based
on DAVID and IPA evaluation. The graph displays major regulated canonical pathways and subnetworks
resulting in cellular functions and molecular fingerprints providing survival advantage for malignant cells with
promotion to further progression and metastasis.
https://doi.org/10.1371/journal.pone.0176167.g004
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relatively limited number of patient samples. The mass spectrometry data represent the initial
stage of a protein sequence database for metastatic melanoma. The combined knowledge of
the tumor cellular composition with protein expression of each metastasis enables identifica-
tion of novel, significantly regulated proteins, in melanoma tumor tissue sections. Upon fur-
ther validation and development these proteins might serve as future diagnostic markers for
this cancer. In Fig 4, the key upstream regulators, the major regulated canonical pathways
and subnetworks according to analysis based on DAVID and IPA evaluation are summarized.
Cellular functions and molecular fingerprints that provide survival advantage for malignant
cells with promotion to further disease progression were highly represented in our overall
analysis. In addition, several markers previously related to melanoma were seen to correlate to
the tissue tumor cell content. Although the translational impact of this feasibility study is not
immediate, future studies should confirm the relevance of such proteins as important mela-
noma landmarks.
Supporting information
S1 Fig. (A) First, (B) second and (C) third most significant biological relationship subnet-
works resulting from Ingenuity Pathways Analysis (IPA) for the proteins correlated to tumor
content. Members of the original list of 359 proteins marked in grey. Magenta outline high-
lights proteins implicated in cancer according to IPA database.
(TIF)
S2 Fig. Subcellular locations and biological relationship network for proteins differentiat-
ing between survivors and non-survivors. Only significant proteins were shown (t-test,
p-value below 0.01). Known cancer biomarkers marked by magenta outline (IPA). Proteins
having no IPA relationships within the presented set are excluded. Red filling: proteins with
higher expression in non-survivors.
(TIF)
S3 Fig. (A) First, (B) second, (C) third and (D) fourth, respectively, most significant biological
relationship subnetworks resulting from Ingenuity Pathways Analysis for the proteins differ-
entiating between survivors and non-survivors. Only significant proteins used in the IPA anal-
ysis (T-test p-value below 0.01). Known cancer biomarkers marked by magenta outline. Red
filling: proteins with higher expression in non-survivors.
(TIF)
S1 Table. Proteins significantly positively correlated to tumor content.
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S2 Table. Proteins significantly negatively correlated to tumor content.
(XLSX)
S3 Table. Correlation of protein expression to disease outcome. Student’s t-test p-value pro-
vided for comparison of survivors vs non-survivors. PSM counts compared, three patients in a
group, each in triplicate, hence 9 samples per group.
(XLSX)
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